Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes
The tumor is a hostile microenvironment for T lymphocytes. Indeed, irregular blood flow, and
endothelial cell (EC) anergy that characterize most solid tumors hamper leukocyte adhesion …
endothelial cell (EC) anergy that characterize most solid tumors hamper leukocyte adhesion …
Adoptive T‐cell therapy for cancer: The era of engineered T cells
Tumors originate from a number of genetic events that deregulate homeostatic mechanisms
controlling normal cell behavior. The immune system, devoted to patrol the organism against …
controlling normal cell behavior. The immune system, devoted to patrol the organism against …
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy
Abnormal tumor vasculature impairs T lymphocyte adhesion to endothelial cells and
lymphocyte extravasation into neoplastic tissues, limiting the therapeutic potential of both …
lymphocyte extravasation into neoplastic tissues, limiting the therapeutic potential of both …
T-cell immunotherapies targeting histocompatibility and tumor antigens in hematological malignancies
V Janelle, C Rulleau, S Del Testa, C Carli… - Frontiers in …, 2020 - frontiersin.org
Over the last decades, T-cell immunotherapy has revealed itself as a powerful, and often
curative, strategy to treat blood cancers. In hematopoietic cell transplantation, most of the so …
curative, strategy to treat blood cancers. In hematopoietic cell transplantation, most of the so …
Next-generation leukemia immunotherapy
Allogeneic hematopoietic cell transplantation led to the discovery of the allogeneic GVL
effect, which remains the most convincing evidence that immune cells can cure cancer in …
effect, which remains the most convincing evidence that immune cells can cure cancer in …
[HTML][HTML] Galectin-3 in prostate cancer stem-like cells is immunosuppressive and drives early metastasis
Galectin-3 (Gal-3) is an extracellular matrix glycan-binding protein with several
immunosuppressive and pro-tumor functions. The role of Galectin-3 in cancer stem-like cells …
immunosuppressive and pro-tumor functions. The role of Galectin-3 in cancer stem-like cells …
Boosting interleukin‐12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR‐tagged nanogold
AM Gasparri, A Sacchi, V Basso, F Cortesi, M Freschi… - Small, 2019 - Wiley Online Library
The clinical use of interleukin‐12 (IL12), a cytokine endowed with potent immunotherapeutic
anticancer activity, is limited by systemic toxicity. The hypothesis is addressed that gold …
anticancer activity, is limited by systemic toxicity. The hypothesis is addressed that gold …
Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice
RM Gorczynski, DA Clark, N Erin, I Khatri - Breast cancer research and …, 2011 - Springer
Previous studies have confirmed that levels of CD200 expression on the cells of the
transplantable EMT6 mouse breast cancer line are increased markedly during growth in …
transplantable EMT6 mouse breast cancer line are increased markedly during growth in …
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses
E Jachetti, S Mazzoleni, M Grioni, A Ricupito… - …, 2013 - Taylor & Francis
According to the cancer stem cell (CSC) theory, therapies that do not target the CSC
compartment have limited, if any, chances to eradicate established tumors. While cytotoxic T …
compartment have limited, if any, chances to eradicate established tumors. While cytotoxic T …
T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFα expression and empower adoptive cell therapy for solid tumors
Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT) effects likely due to
the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility …
the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility …